Cambridge Investment Research Advisors’s Niagen Bioscience, Inc. Common Stock NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-92,650
| Closed | -$338K | – | 3619 |
|
|
2024
Q3 | $338K | Sell |
92,650
-22,150
| -19% | -$80.8K | ﹤0.01% | 2743 |
|
|
2024
Q2 | $313K | Sell |
114,800
-8,500
| -7% | -$23.2K | ﹤0.01% | 2673 |
|
|
2024
Q1 | $429K | Buy |
123,300
+5,510
| +5% | +$19.2K | ﹤0.01% | 2404 |
|
|
2023
Q4 | $168K | Sell |
117,790
-5,128
| -4% | -$7.31K | ﹤0.01% | 2947 |
|
|
2023
Q3 | $179K | Sell |
122,918
-25,425
| -17% | -$37K | ﹤0.01% | 2852 |
|
|
2023
Q2 | $233K | Sell |
148,343
-46,215
| -24% | -$72.6K | ﹤0.01% | 2753 |
|
|
2023
Q1 | $298K | Buy |
194,558
+68,000
| +54% | +$104K | ﹤0.01% | 2498 |
|
|
2022
Q4 | $213K | Buy |
126,558
+7,000
| +6% | +$11.8K | ﹤0.01% | 2709 |
|
|
2022
Q3 | $147K | Buy |
119,558
+27,650
| +30% | +$34K | ﹤0.01% | 2787 |
|
|
2022
Q2 | $153K | Sell |
91,908
-5,500
| -6% | -$9.16K | ﹤0.01% | 2793 |
|
|
2022
Q1 | $240K | Buy |
97,408
+22,500
| +30% | +$55.4K | ﹤0.01% | 2737 |
|
|
2021
Q4 | $280K | Buy |
74,908
+6,050
| +9% | +$22.6K | ﹤0.01% | 2584 |
|
|
2021
Q3 | $432K | Buy |
68,858
+50
| +0.1% | +$314 | ﹤0.01% | 2158 |
|
|
2021
Q2 | $678K | Buy |
68,808
+11,175
| +19% | +$110K | ﹤0.01% | 1818 |
|
|
2021
Q1 | $538K | Sell |
57,633
-27,100
| -32% | -$253K | ﹤0.01% | 1851 |
|
|
2020
Q4 | $407K | Buy |
84,733
+48,750
| +135% | +$234K | ﹤0.01% | 1912 |
|
|
2020
Q3 | $144K | Buy |
+35,983
| New | +$144K | ﹤0.01% | 2325 |
|